SGMO News and Press, Sangamo Therapeutics Inc. From 05/21/21

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4 th at 11am Eastern Time. The virtual session will be webcast live and may be access...

Image source: The Motley Fool. Sangamo Therapeutics Inc (NASDAQ: SGMO) Q1 2021 Earnings Call May 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Sangamo Therapeutics Inc (SGMO) Q1 2021 Earnings Call Transcript

Sangamo Therapeutics, Inc. (SGMO) Q1 2021 Earnings Conference Call May 4, 2021 05:00 PM ET Company Participants Aron Feingold - Head of Corporate Communications and Investor Relations Officer Sandy Macrae - President and Chief Executive Officer Robert Schott - Senior Vice President and Head o...

The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Sangamo Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Sangamo Therapeutics (SGMO) is down 2.3% after-hours after its Q1 net loss widened year-over-year and it missed on EPS.Q1 net loss was $45.9M ($0.32 per share), compared to a net loss of $42.9M ($0.37 per share) in the prior-year period.Revenues doubled in the quarter to $26.3M from $13....

Sangamo Therapeutics (SGMO): Q1 GAAP EPS of -$0.32 misses by $0.02.Revenue of $26.28M (+100.9% Y/Y) beats by $2.08M.Guidance for 2021 Reiterated (initial guidance provided on February 24, 2021).On a GAAP basis, we expect total operating expenses, including non-cash stock-based compensation ex...

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results. “This quarter, we have continued our focus o...

Having initiated CRISPR Therapeutics ([[CRSP]] -6.0%) with a sector perform rating in October, RBC Capital Markets has added four more gene-editing stocks into its coverage.The analysts Luca Issi and Lisa Walter have issued outperform ratings on Intellia Therapeutics ([[NTLA]] -2.9%) and Sang...

Sangamo Therapeutics (NASDAQ:SGMO) is scheduled to announce Q1 earnings results on Tuesday, May 4th, after market close.The consensus EPS Estimate is -$0.30 and the consensus Revenue Estimate is $24.2M (+85.0% Y/Y).Over the last 2 years, SGMO has beaten EPS estimates 50% of the time and has b...

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021, in a virtual format. “Our zinc finger tech...